Term ends Dec 8, 2029 · High confidence
Held by Amgen Inc.
Filed Apr 26, 2013 as application 29/453,258 · Granted Dec 8, 2015
Base term, 14 years from grant
Today
2015
2029
Clock starts
Dec 8, 2015
Dec 8, 2015
Term ends
Dec 8, 2029
Dec 8, 2029
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
14 years from grant
Base term
No maintenance fees are payable on this kind of patent.
16
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its base term, 14 years from grant, with no adjustment for prosecution delay. No maintenance fees are payable on this kind of patent. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 14 years from grant | Granted Dec 8, 2015 | Dec 8, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Computed term end | The steps above, in order | Dec 8, 2029 | High confidence |
This family
| US 8,939,935 | In force Aug 2032 | Aug 2032 |
| US 9,511,189 | In force Jan 2033 | Jan 2033 |
| US 9,707,337 | In force Jun 2033 | Jun 2033 |
| US D745,142 | this patent Dec 2029 | Dec 2029 |
| US 9,814,832 | In force Jan 2034 | Jan 2034 |
| Application PCT/US2014/013005 | PCT application no patent term | no patent term |
| US 9,707,335 | In force Mar 2034 | Mar 2034 |
| US 9,999,727 | In force no later than Apr 2034 | no later than Apr 2034 |
8 of 16 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 2, 2013 Reel 30730, frame 284 | O'connor, Sean M.; Bokelman, Kevin; Hanson, Ian B.; Bente, Paul F., IV; Wu, Kun-chi | Unitract Syringe Pty Ltd. | Assignment of Assignor's Interest |
| Mar 13, 2014 Reel 32446, frame 319 | Unitract Syringe Pty Ltd. | Ros Acquisition Offshore LP | Security Interest |
| Aug 8, 2017 Reel 43482, frame 722 | Unilife Corporation; Unilife Medical Solutions, Inc.; Unitract Syringe Pty Ltd. Acn 101 059 723; Unilife Medical Solutions Pty Limited Acn 008 071 403 | Unl Holdings LLC | Assignment of Assignor's Interest |
| Oct 9, 2025 Reel 73057, frame 641 | Unl Holdings LLC | Amgen Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center
No maintenance fees are payable on this kind of patent, so the record carries no fee events.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2029
Term ends Dec 8, 2029. No maintenance fees are payable on this kind of patent
Citations
54
later US patents cite this one
That is top 25% of design patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.